BrainsWay Ltd. (TLV:BWAY)
Israel · Delayed Price · Currency is ILS · Price in ILA | Market Cap | 1.76B +199.7% |
| Revenue (ttm) | 177.50M +29.4% |
| Net Income | 27.65M +123.6% |
| EPS | 0.69 +176.9% |
| Shares Out | 40.04M |
| PE Ratio | 63.46 |
| Forward PE | 57.62 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 160,720 |
| Average Volume | 113,971 |
| Open | 4,263.00 |
| Previous Close | 4,436.00 |
| Day's Range | 4,263.00 - 4,444.00 |
| 52-Week Range | 1,753.00 - 5,123.00 |
| Beta | 0.22 |
| RSI | 41.04 |
| Earnings Date | May 13, 2026 |
About BrainsWay
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company prim... [Read more]
Financial Performance
In 2025, BrainsWay's revenue was $52.23 million, an increase of 27.33% compared to the previous year's $41.02 million. Earnings were $7.58 million, an increase of 159.33%.
Financial numbers in USD Financial StatementsNews
Brainsway announces $1.5M investment in APS Innovations
BrainsWay (BWAY) announced it has entered into a strategic equity financing agreement with APS Innovations, the parent company of Advanced Psychiatric Management, a management services organization se...
BrainsWay Announces Minority-Stake Investment in Hopemark Health
Investment in provider servicing clinics in Illinois is latest in series of similar transactions by BrainsWay with leading North American mental health providers to raise awareness and expand access t...
Brainsway reports Q1 EPS 6c, consensus 5c
Reports Q1 revenue $15.53M, consensus $14.62M. “We are off to an excellent start in 2026, delivering 35% revenue growth in the first quarter while generating $2.8 million of Adjusted EBITDA,”…
Brainsway backs FY26 revenue view $66M-$68M, consensus $66.44M
Backs FY26 adjusted EBITDA view $12M-$14M. “We are off to an excellent start in 2026, delivering 35% revenue growth in the first quarter while generating $2.8 million of Adjusted EBITDA,”…
BrainsWay Reports First Quarter 2026 Financial Results and Operational Highlights
R evenue grew approximately 35 % y ear- o ver- y ear to $1 5 .5 million for Q1 2026
BrainsWay to Report First Quarter 2026 Financial Results on May 13, 2026
BURLINGTON, Mass. and JERUSALEM, April 29, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation techno...
BrainsWay Highlights Growing U.S. Payer Support for Nurse Practitioner-Administered Transcranial Magnetic Stimulation (TMS) Therapy
Growing payer acceptance of nurse practitioner administration of Deep TMS is expected to expand access to non‑drug mental health treatments Growing payer acceptance of nurse practitioner administratio...
BrainsWay to Participate in the 25th Annual Needham Virtual Healthcare Conference
BURLINGTON, Mass. and JERUSALEM, April 13, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatm...
Brainsway completes revenue-based milestone investment into Axis Integrated
BrainsWay (BWAY) has completed a $1M milestone-based investment in Axis Integrated Mental Health, a management services organization servicing several mental health clinics in Colorado. The investment...
BrainsWay Completes Revenue-Based Milestone Investment into Axis Integrated Mental Health
BrainsWay's investment is part of its ongoing strategy to partner with leading U.S. mental health providers to increase access to care BrainsWay's investment is part of its ongoing strategy to partner...
Brainsway price target adjusted to $15 at H.C. Wainwright after ADS ratio change
H.C. Wainwright lowered the firm’s price target on Brainsway (BWAY) to $15 from $30 and keeps a Buy rating on the shares to reflect the recent change effected in the…
Brainsway reports Q4 EPS 7c, consensus 3c
Reports Q4 revenue $14.5M, consensus $14.02M. “We successfully closed out 2025 with strong momentum across our business, delivering 27% full-year revenue growth while significantly expanding profitabi...
Brainsway sees FY26 revenue $66M-$68M, consensus $64.79M
The Company anticipates continued profitability and positive cash flow, targeting operating income of 13% to 14% and Adjusted EBITDA of $12 to $14 million.
BrainsWay Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
BURLINGTON, Mass. and JERUSALEM, March 11, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatm...
Brainsway announces new data on noninvasive way to treat depression
BrainsWay (BWAY) unveiled new clinical data showing a faster, noninvasive way to treat depression without compromising the efficacy of one of psychiatry’s most impactful treatments. The milestone adva...
Landmark Data Validate BrainsWay's SWIFT™ Deep TMS, Beginning a New Era in Depression Treatment
World's only FDA-cleared Deep TMS™ accelerated treatment reduces the acute phase of treatment by 70% World's only FDA-cleared Deep TMS™ accelerated treatment reduces the acute phase of treatment by 70...
BrainsWay to Report Fourth Quarter and Full Year 2025 Financial Results on March 11, 2026
BURLINGTON, Mass. and JERUSALEM, Feb. 25, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation technol...
Brainsway announces new minority-stake investment in BrainStim Health
BrainsWay (BWAY) announced it has entered into a strategic equity financing agreement with BrainStim Health, a provider based in British Columbia servicing a growing number of mental health clinics in...
BrainsWay Announces New Minority-Stake Investment in Canadian Provider, BrainStim Health Inc.
BrainsWay continues to activel y evaluat e similar investments in l eading North American m ental h ealth p roviders to raise awareness and e xpand a ccess to transformative care
Brainsway says Cigna’s Evernorth to eliminate authorization requirement for TMS
BrainsWay (BWAY) commented on the recent news issued by Evernorth Behavioral Health, a division of the Cigna Group (CI), which serves over 18 million covered lives across 12 states, that…
BrainsWay Reports Cigna's Evernorth Behavioral Health to Eliminate Prior Authorization Requirements for TMS Coverage, Accelerating Access to Care
BURLINGTON, Mass. and JERUSALEM, Feb. 18, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation techno...
Brainsway announces change in ADS-to-ordinary share ratio
BrainsWay’s (BWAY) Board of Directors approved a plan to change to the ratio of its American Depositary Shareslisted on the Nasdaq Capital Market relative to its ordinary shares traded on…
BrainsWay Announces Change in ADS-to-Ordinary Share Ratio
Change in ADS ratio aimed at simplifying comparisons to ordinary shares traded on the Tel Aviv Stock Exchange, while boosting liquidity and access for U.S. investors Change in ADS ratio aimed at simpl...
Brainsway management to meet virtually with Northland
Virtual Meeting to be held on February 17 at 10 am hosted by Northland.
Brainsway price target raised to $30 from $24 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Brainsway (BWAY) to $30 from $24 and keeps a Buy rating on the shares. The company recently announced premarket approval receipt for…